Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 1449 • ACR Convergence 2023
Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Dennisse Bonilla², Zareen Ahmad¹, Arthur Bookman³, Linda Hiraki⁴, Earl Silverman⁵, Mohammad Movahedi¹, Sindhu Johnson⁶ and Hana Salem Alahmari⁷, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Silverman, Toronto, ON, Canada, ⁶Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁷Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To evaluate the development of a systemic autoimmune rheumatic disease (SARD) in undifferentiated and asymptomatic individuals with antinuclear antibodies (ANA). We evaluated fulfillment of…
Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Shreena Kamlesh Gandhi¹, Abhiram Challa², Sandhya Shri Kanniyaram³, Arnav Kamat⁴, Tejasri Polana⁵ and Kaleb Michaud⁶, ¹Kansas University School of Medicine, Wichita, KS, ²KU School of Medicine, Wichita, KS, ³John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ⁴NYCH+H/Woodhull, New York, NY, ⁵Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
Abstract Number: 1483 • ACR Convergence 2023
High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study
Shiori Nakagawa, Yasunori Iwata, Takahiro Yuasa, Keisuke Sako, Keisuke Horikoshi, Taichiro Minami, Megumi Oshima, Tadashi Toyama, Shinji Kitajima, Akinori Hara, Norihiko Sakai, Miho Shimizu and Takashi Wada, Department of Nephrology, Kanazawa University Hospital, Kanazawa, Japan
Background/Purpose: Lupus nephritis (LN) is a major manifestation which develops in more than 50% of patients with systemic lupus erythematosus (SLE), and is also a…
Abstract Number: 1500 • ACR Convergence 2023
Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
Saira Sheikh¹, Kevin Withrop², Jinoos Yazdany³, Sandra Navarra⁴, Tatsuya Atsuma⁵, Paula Curtis⁶, Jose Miyar Olaiz⁷, Christine Henning⁸, Roger A. Levy⁹, William Stohl¹⁰ and Daniel Wallace¹¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁶GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁷GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁹GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹⁰University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
Abstract Number: 1597 • ACR Convergence 2023
Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus
Wangbin Ning, Gary Gilkeson and Wei Jiang, Medical University of South Carolina, Charleston, SC
Background/Purpose: There is an intricate interplay between the microbiome and the immune response impacting the development of normal immunity and autoimmunity. However, we do not…
Abstract Number: 1694 • ACR Convergence 2023
Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE
Prathyusha Bachali¹, Shimon Korish², Yanhua Hu³, Peter Schafer⁴, Amrie Grammer¹ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Bristol Myers Squibb, Summit, NJ, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Belle Mead, NJ
Background/Purpose: Iberdomide is a high affinity cereblon ligand that promotes ubiquitylation and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors and, thereby altering…
Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: 2265 • ACR Convergence 2023
Lupus Damage Index Revision – Item Generation and Reduction Phase
Burak Kundakci¹, Megan Barber², Ann Clarke², Sindhu Johnson³, Ian Bruce⁴ and On behalf of the revised SLE organ damage index (SDI) collaborators⁴, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, ²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: The SDI is a robust instrument, but is limited by incomplete items, restricted applicability in paediatric patients, and outdated item definitions1. The SLICC, ACR…
Abstract Number: 2282 • ACR Convergence 2023
Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Arthur Mageau¹, Christel Gerardin², Kankoe Sallah², Jean-Francois Timsit¹, Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France
Background/Purpose: The SARS-CoV2 pandemic reopened the unresolved question of whether and how a viral infection can trigger flares of immune-mediated inflammatory diseases such as systemic…
Abstract Number: 2299 • ACR Convergence 2023
Medication-related Hospitalizations in Systemic Lupus Erythematosus
Michele Stanciu¹, Evelyne Vinet², Emily Gibson McDonald³, Gregory Clark³, Christian Pineau², Fares Kalache⁴, Louis-Pierre Grenier⁵, Sasha Bernatsky⁶ and Arielle Mendel³, ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Carignan, AB, Canada, ⁵Montreal General Hospital, Montréal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Adverse drug events (ADEs; harm from use of a drug) cause a significant burden to the healthcare system, with an estimated 5% of hospitalizations…
Abstract Number: 2315 • ACR Convergence 2023
Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London
Samir Patel¹, Shounak Ghosh², Rajagopal Sankara Narayanan³, Letizia Valisena⁴, Deepak Nagra¹, Jonathan Dick⁴, Kate Bramham⁴, Patrick Gordon⁵ and Chris Wincup⁴, ¹King's College London, London, United Kingdom, ²CMRI Hospital, Kolkata, India, ³Narayana Medical College, Nellore, India, ⁴King's College Hospital, London, United Kingdom, ⁵NHS, London, United Kingdom
Background/Purpose: Lupus nephritis represents a severe manifestation of SLE and is associated with a risk of progression to end-stage kidney disease (ESKD) if untreated, leading…
Abstract Number: 2332 • ACR Convergence 2023
Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data
Anca Askanase¹, Christian Stach², Claire Brittain³, George Stojan⁴ and Richard Furie⁵, ¹Columbia University Medical Center, New York, NY, ²UCB Pharma, Monheim am Rheim, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB, Baltimore, MD, ⁵Northwell Health, Manhasset, NY
Background/Purpose: Systemic lupus erythematosus (SLE) clinical trials are challenged by high standard of care plus placebo (SOC+PBO) response rates.1 Previous post hoc analyses of the…
Abstract Number: 2351 • ACR Convergence 2023
Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years
Yan Chen¹, Karen Worley², Brendan Rabideau¹, Bernard Rubin³, Benson Wu¹, Rose Chang¹ and Maral DerSarkissian¹, ¹Analysis Group, Boston, MA, ²GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ³GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: BEL efficacy in pts with SLE has been previously demonstrated in clinical and real-world studies.1 However, there are limited data on differences in outcomes…
Abstract Number: 2488 • ACR Convergence 2023
Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
Joan Merrill¹, Yoshiya Tanaka², David D'Cruz³, Karina Vila-Rivera⁴, Daniel Siri⁵, Xiaofeng Zeng⁶, Kristin D'Silva⁷, Ling Cheng⁷, Thierry Sornasse⁷, Thao Doan⁷, Denise Kruzikas⁷ and Alan Friedman⁷, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³King's College London, London, United Kingdom, ⁴GCM Medical, San Juan, PR, ⁵CAICI SRL, Rosario, Argentina, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷AbbVie, Inc., North Chicago, IL
Background/Purpose: ABBV-599 is a novel combination of elsubrutinib (ELS; a selective BTK inhibitor) and upadacitinib (UPA; a JAK inhibitor) that targets non-overlapping signaling pathways associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].